50 related articles for article (PubMed ID: 20539208)
1. A phase 1 safety study of an IRX-2 regimen in patients with squamous cell carcinoma of the head and neck.
Freeman SM; Franco JL; Kenady DE; Baltzer L; Roth Z; Brandwein HJ; Hadden JW
Am J Clin Oncol; 2011 Apr; 34(2):173-8. PubMed ID: 20539208
[TBL] [Abstract][Full Text] [Related]
2. Novel neoadjuvant immunotherapy regimen safety and survival in head and neck squamous cell cancer.
Wolf GT; Fee WE; Dolan RW; Moyer JS; Kaplan MJ; Spring PM; Suen J; Kenady DE; Newman JG; Carroll WR; Gillespie MB; Freeman SM; Baltzer L; Kirkley TD; Brandwein HJ; Hadden JW
Head Neck; 2011 Dec; 33(12):1666-74. PubMed ID: 21284052
[TBL] [Abstract][Full Text] [Related]
3. Increased lymphocyte infiltration in patients with head and neck cancer treated with the IRX-2 immunotherapy regimen.
Berinstein NL; Wolf GT; Naylor PH; Baltzer L; Egan JE; Brandwein HJ; Whiteside TL; Goldstein LC; El-Naggar A; Badoual C; Fridman WH; White JM; Hadden JW
Cancer Immunol Immunother; 2012 Jun; 61(6):771-82. PubMed ID: 22057678
[TBL] [Abstract][Full Text] [Related]
4. Implications and Emerging Therapeutic Avenues of Inflammatory Response in HPV+ Head and Neck Squamous Cell Carcinoma.
Castellano LRC; Cruz SBSC; Hier M; Bonan PRF; Alaoui-Jamali MA; da Silva SD
Cancers (Basel); 2022 Nov; 14(21):. PubMed ID: 36358823
[TBL] [Abstract][Full Text] [Related]
5. An Update on the Immunotherapy for Oropharyngeal Squamous Cell Carcinoma.
Huang Y; Lan Y; Zhang Z; Xiao X; Huang T
Front Oncol; 2022; 12():800315. PubMed ID: 35372036
[TBL] [Abstract][Full Text] [Related]
6. Preoperative Immunotherapy in the Multidisciplinary Management of Oral Cavity Cancer.
Philips R; Han C; Swendseid B; Curry J; Argiris A; Luginbuhl A; Johnson J
Front Oncol; 2021; 11():682075. PubMed ID: 34277428
[TBL] [Abstract][Full Text] [Related]
7. Potential Use of Gluconate in Cancer Therapy.
Mycielska ME; Mohr MTJ; Schmidt K; Drexler K; Rümmele P; Haferkamp S; Schlitt HJ; Gaumann A; Adamski J; Geissler EK
Front Oncol; 2019; 9():522. PubMed ID: 31275855
[TBL] [Abstract][Full Text] [Related]
8. IRX-2 natural cytokine biologic for immunotherapy in patients with head and neck cancers.
Wolf GT; Moyer JS; Kaplan MJ; Newman JG; Egan JE; Berinstein NL; Whiteside TL
Onco Targets Ther; 2018; 11():3731-3746. PubMed ID: 29988729
[TBL] [Abstract][Full Text] [Related]
9. Increased immune infiltration and chemokine receptor expression in head and neck epithelial tumors after neoadjuvant immunotherapy with the IRX-2 regimen.
Berinstein NL; McNamara M; Nguyen A; Egan J; Wolf GT
Oncoimmunology; 2018; 7(5):e1423173. PubMed ID: 29721379
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic vaccines for high-risk HPV-associated diseases.
Chabeda A; Yanez RJR; Lamprecht R; Meyers AE; Rybicki EP; Hitzeroth II
Papillomavirus Res; 2018 Jun; 5():46-58. PubMed ID: 29277575
[TBL] [Abstract][Full Text] [Related]
11. Novel Immunotherapeutic Approaches for Head and Neck Squamous Cell Carcinoma.
Bann DV; Deschler DG; Goyal N
Cancers (Basel); 2016 Sep; 8(10):. PubMed ID: 27669306
[TBL] [Abstract][Full Text] [Related]
12. [Immunomodulation as innovative therapy for head and neck tumors : Current developments].
Schuler PJ; Doescher JC; Laban S; Hoffmann TK
HNO; 2016 Jul; 64(7):470-8. PubMed ID: 26912050
[TBL] [Abstract][Full Text] [Related]
13. Immunostimulatory Activity of the Cytokine-Based Biologic, IRX-2, on Human Papillomavirus-Exposed Langerhans Cells.
Da Silva DM; Woodham AW; Naylor PH; Egan JE; Berinstein NL; Kast WM
J Interferon Cytokine Res; 2016 May; 36(5):291-301. PubMed ID: 26653678
[TBL] [Abstract][Full Text] [Related]
14. Peptide Based Vaccine Approaches for Cancer-A Novel Approach Using a WT-1 Synthetic Long Peptide and the IRX-2 Immunomodulatory Regimen.
Naylor PH; Egan JE; Berinstein NL
Cancers (Basel); 2011 Oct; 3(4):3991-4009. PubMed ID: 24213121
[TBL] [Abstract][Full Text] [Related]
15. Tailored immunotherapy for HPV positive head and neck squamous cell cancer.
Gildener-Leapman N; Lee J; Ferris RL
Oral Oncol; 2014 Sep; 50(9):780-4. PubMed ID: 24126224
[TBL] [Abstract][Full Text] [Related]
16. A phase 1b study of humanized KS-interleukin-2 (huKS-IL2) immunocytokine with cyclophosphamide in patients with EpCAM-positive advanced solid tumors.
Connor JP; Cristea MC; Lewis NL; Lewis LD; Komarnitsky PB; Mattiacci MR; Felder M; Stewart S; Harter J; Henslee-Downey J; Kramer D; Neugebauer R; Stupp R
BMC Cancer; 2013 Jan; 13():20. PubMed ID: 23320927
[TBL] [Abstract][Full Text] [Related]
17. [Immunotherapy of head and neck cancer. Current developments].
Schuler PJ; Hoffmann TK; Gauler TC; Bergmann C; Brandau S; Lang S
HNO; 2013 Jul; 61(7):559-72. PubMed ID: 23247754
[TBL] [Abstract][Full Text] [Related]
18. IRX-2, a novel immunotherapeutic, enhances and protects NK-cell functions in cancer patients.
Schilling B; Halstead ES; Schuler P; Harasymczuk M; Egan JE; Whiteside TL
Cancer Immunol Immunother; 2012 Sep; 61(9):1395-405. PubMed ID: 22270713
[TBL] [Abstract][Full Text] [Related]
19. A short course of neoadjuvant IRX-2 induces changes in peripheral blood lymphocyte subsets of patients with head and neck squamous cell carcinoma.
Whiteside TL; Butterfield LH; Naylor PH; Egan JE; Hadden JW; Baltzer L; Wolf GT; Berinstein NL
Cancer Immunol Immunother; 2012 Jun; 61(6):783-8. PubMed ID: 22109700
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
